Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma A/S (Nasdaq: ASND) presented findings from its rare disease endocrinology programs at ENDO Online 2020. The fliGHt Trial showed that patients can safely switch from daily somatropin to TransCon hGH, maintaining consistent efficacy. Interim data from the heiGHt Trial reaffirmed height advantages beyond one year of therapy. The company plans to submit marketing applications in the U.S. this quarter and in Europe by Q3. Additionally, promising data for TransCon PTH highlights its potential as a replacement therapy for hypoparathyroidism.
Ascendis Pharma (ASND) reported its Q1 2020 financial results, revealing a net loss of €63.3 million, or €1.32 per share, versus €53.6 million, or €1.24 per share, in Q1 2019. Revenue dropped to €2.2 million from €5.4 million year-over-year, primarily due to decreased license and service revenue. The company is on track to file a Biologics License Application for TransCon hGH in Q2 and advance its European submission to Q3. Ascendis Pharma ended Q1 with €534.4 million in cash, a decrease from €598.1 million at the end of 2019. R&D expenses rose to €57.5 million, reflecting ongoing product development efforts.
Ascendis Pharma A/S (NASDAQ: ASND) announced a conference call and live webcast on May 19, 2020, at 4:30 p.m. ET to discuss its Q1 2020 financial results and provide a business update. The call can be accessed via a dial-in number or through the company's website, where a replay will be available for 30 days following the event. Ascendis Pharma focuses on innovative therapies using its TransCon™ platform, with ongoing clinical development in endocrinology and oncology.